Stock NAUT NAUTILUS BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Nautilus Biotechnology, Inc.

Equities

NAUT

US63909J1088

Real-time Estimate Cboe BZX
Other stock markets
 12:06:09 2024-04-29 pm EDT 		5-day change 1st Jan Change
2.55 USD +2.41% Intraday chart for Nautilus Biotechnology, Inc. +6.20% -14.05%
Feb. 28 Transcript : Nautilus Biotechnology, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28 Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Nautilus Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c59a66bd11ac5c.7ZtcT15C6X2e7lYHGJV7nqJP6aUjw1p5xzSND86zqNg.mtQSAwYO2ifHhCcyfdgu78oemPpUihkM9XP7WPrm3-Gb3QNiEzGAOcyhBw~5aa2260fdfc8f5848a0881c91a485817

Analyst Recommendations on Nautilus Biotechnology, Inc.

Goldman Sachs Halves Price Target on Nautilus Biotechnology to $2 From $4 Amid Product Launch Delay; Neutral Rating Kept MT
Morgan Stanley Lowers Nautilus Biotechnology's Price Target to $6 From $8, Maintains Equalweight Rating MT
Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $4 from $5, Keeps Neutral Rating MT
Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $5 from $9, Keeps Neutral Rating MT
Morgan Stanley Initiates Nautilus Biotechnology at Equalweight With $8 Price Target, Sees Commercialization Key to Unlocking Upside MT
Cowen Initiates Coverage on Nautilus Biotechnology With Outperform Rating MT
NAUTILUS BIOTECHNOLOGY : Goldman Sachs Starts Nautilus Biotechnology at Neutral With $10 Price Target MT
NAUTILUS BIOTECHNOLOGY : Jefferies Starts Nautilus Biotechnology at Buy With $13 Price Target MT
NAUTILUS BIOTECHNOLOGY : Jefferies Initiates Coverage on Nautilus Biotechnology With Buy Rating, $13 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.49 USD
Average target price
4.25 USD
Spread / Average Target
+70.68%
High Price Target
5 USD
Spread / Highest target
+100.80%
Low Price Target
2.75 USD
Spread / Lowest Target
+10.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nautilus Biotechnology, Inc.

Goldman Sachs
Morgan Stanley
Cowen
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NAUT Stock
  4. Consensus Nautilus Biotechnology, Inc.